Aigen Sciences Overview
- Year Founded
-
2021
- Status
-
Private
- Employees
-
29
- Latest Deal Type
-
Series A
- Latest Deal Amount
-
$8.78M
- Investors
-
10
Aigen Sciences General Information
Description
Operator of an artificial intelligence (AI) based new drug development platform intended to discover high-potency drugs. The company's platform accelerates the development of therapies by combining scientific expertise with autonomous AI systems, enabling pharmaceutical researchers to get effective drugs and achieve higher success rates in clinical trials while reducing costs and improving efficiency.
Contact Information
Website
www.aigensciences.comCorporate Office
- Office 703, 58 Wangsimni-ro
- Seongdong-gu
- Seoul, 04778
- South Korea
Corporate Office
- Office 703, 58 Wangsimni-ro
- Seongdong-gu
- Seoul, 04778
- South Korea
Aigen Sciences Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Early Stage VC (Series A) | 11-Jul-2025 | $8.78M | Completed | Generating Revenue | ||
| 2. Seed Round | 04-Oct-2022 | Completed | Generating Revenue | |||
| 1. Accelerator/Incubator | Completed | Generating Revenue |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Aigen Sciences Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Aigen Sciences Patents
Aigen Sciences Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026127574-A1 | Fused heterocyclic compound | Pending | 10-Dec-2024 | ||
| WO-2025143733-A1 | Novel inhibitors of ubiquitin-specific peptidase 1 | Inactive | 26-Dec-2023 | ||
| EP-4737452-A1 | Novel pyrimidine derivatives | Pending | 29-Jun-2023 | ||
| WO-2025005744-A1 | Novel pyrimidine derivatives | Inactive | 29-Jun-2023 | ||
| EP-4737453-A1 | Novel selenophene derivatives | Pending | 29-Jun-2023 | A61P35/00 |
Aigen Sciences Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Aigen Sciences Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hyosung Ventures | Corporate Venture Capital | Minority | ||
| K2 Investment Partners | Venture Capital | Minority | ||
| Premier Partners | PE/Buyout | Minority | ||
| Scale Up Partners | Accelerator/Incubator | Minority | ||
| Bluepoint | Venture Capital | Minority |
Aigen Sciences FAQs
-
When was Aigen Sciences founded?
Aigen Sciences was founded in 2021.
-
Where is Aigen Sciences headquartered?
Aigen Sciences is headquartered in Seoul, South Korea.
-
What is the size of Aigen Sciences?
Aigen Sciences has 29 total employees.
-
What industry is Aigen Sciences in?
Aigen Sciences’s primary industry is Drug Delivery.
-
Is Aigen Sciences a private or public company?
Aigen Sciences is a Private company.
-
What is Aigen Sciences’s current revenue?
The current revenue for Aigen Sciences is .
-
How much funding has Aigen Sciences raised over time?
Aigen Sciences has raised $11.8M.
-
Who are Aigen Sciences’s investors?
Hyosung Ventures, K2 Investment Partners, Premier Partners, Scale Up Partners, and Bluepoint are 5 of 10 investors who have invested in Aigen Sciences.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
